{"id":"10184967810-77","name":"LEO Pharma A/S","registrationDate":"2012-01-23T13:41:17.428+02:00","category":2,"subCategory":3,"legal":"Limited company","web":"http://www.leo-pharma.com/","country":"Denmark","headAddress":"Industriparken, 55","headCity":"Ballerup","headPostCode":"2750","headPhone":"(45)44 94 58 88","boss":"Gitte Pugholm Aabo","bossTitle":"Ms","bossPosition":"CEO","membersCount":3,"membersFTE":"1.25","membership":"Member of the ​The Danish Association of the Pharmaceutical Industry (Lif)&#xd;\nMember of the International Federation of Pharmaceutical Manufactuers &amp; Associations (IFPMA)&#xd;\nMember of EFPIA&#xd;\nMember of Confederation of Danish Industry (DI)","memberOrga":"","goal":"Founded in 1908, LEO Pharma is an independent, research-based pharmaceutical company.&#xd;<br />&#xd;<br />LEO Pharma develops, manufactures and markets pharmaceutical drugs to dermatologic and thrombotic patients in more than 100 countries globally. To realise our vision of becoming the preferred dermatology care partner improving people’s lives around the world, we are expanding into new regions and markets, reaching more patients and societies with drugs and therapies that address unmet medical needs. &#xd;<br />&#xd;<br />LEO Pharma employs around 5,700 employees worldwide. The company is headquartered in Denmark and is fully owned by the LEO Foundation.","acronym":"LEO Pharma","interests":"Digital economy and society, Public Health","euInitiatives":"REACH&#xd;<br />Incentives Review, including Orphan Medicinal Products Regulation (OMP) &#xd;<br />HTA proposal&#xd;<br />Falsified Medicines Directive","lastUp":"2019-07-09T12:59:45.338+02:00","customers":"","costAbsolu":"","costRange":"200000-299999","turnoverAbsolu":0,"turnoverRange":""}